I heard a great talk yesterday by Dr. Patrik Rorsman from
the University of Oxford, who has a new way of thinking about type 2 diabetes.
He believes some individuals who develop the disease may have a deficit in insulin
exocytosis, but not by the mechanism that anyone would have predicted.
It is abundantly clear that type-2 diabetes is not caused by
a lack of available insulin in the pancreas. Therefore, Dr. Rorsman
hypothesized that the mechanism of exocytic release of insulin may be perturbed
in diabetic patients. However, when he made classical measurements to detect
exocytic release in primary tissues, such as amperometry of cargo release and
monitoring membrane capacitance, he saw no differences between healthy and
diseased cells. It wasn’t until he engineered an elegant ATP-sensitive,
feedback biosensor into his recording set-up that he detected a difference in
exocytosis.
What he found suggests that the equilibrium between
kiss-and-run and full-fusion exocytic events is slightly perturbed in diabetic
tissue, such that insulin-containing granules are a little bit less likely to
fully fuse with the membrane and release all their cargo. During the
kiss-and-run events, the neck of the fusing granule acts as a sieve and
prevents insulin from leaking out. The overall effect of too many kiss-and-run
events then is reduced insulin release and decreased glucose sensitivity.
Furthermore, he found that this subtle change in exocytic
equilibrium in beta cells correlates very well with the expression of Sox4, a
transcription factor identified in a screen of tissues from hundreds of
patients, both diabetic and healthy. Sox4 regulates Amisyn, a syntaxin-6
binding protein that appears to compete with normal SNAREs to inhibit full
granule fusion. Amycin correlated with increased resting blood glucose levels
and decreased insulin release in the patient screen as well, further implying a
link to its role in granule exocytosis.
Dr. Rorsman is interested now in targeting this pathway to
correct the balance of exocytic events in the pancreas and restore glucose
sensitivity to diabetic tissue, and he already has some therapeutic ideas. He
also believes Sox4 expression is likely misregulated in a subset of diabetic
individuals and we should pay attention to it as a potential biomarker for
development of the disease. It will be interesting to know whether some
genotypes are more susceptible to Sox4 misregulation, or if lifestyle also
plays a role in its expression.
Comments
Post a Comment